1. 1. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK (2019) Non-small-cell lung cancers: a heterogeneous set of diseases. Nature Reviews Cancer, 19(11): 665-78.

2. Travis WD, Brambilla E, Noguchi M, Nicholson AG, et al. (2021) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Oncology, 16(7): 1053-78.

3. Campbell JD, Alexandrov A, Kim J, Wala J, et al. (2016) Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nature Genetics, 48(6): 607-16. [DOI:10.1038/ng.3564]

4. Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, et al. (2017) Tracking the evolution of non-small-cell lung cancer. New England Journal of Medicine, 376(22): 2109-21. [DOI:10.1056/NEJMoa1616288]

5. Faber DL, Agbarya A, Lee A, Tsenter Y, et al. (2024) Clinical versus pathological staging in patients with resected ground glass pulmonary lesions. Diagnostics, 14(24): 2874. [DOI:10.3390/diagnostics14242874]

6. Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, et al. (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. New England Journal of Medicine, 378(2): 113-25. [DOI:10.1056/NEJMoa1713137]

7. Summers MA, McCoy KL, Hildreth AF, Morrison SS, et al. (2021) Targeting KRAS G12C in non-small-cell lung cancer. New England Journal of Medicine, 384(25): 2371-81.

8. Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. New England Journal of Medicine. 2020;383(18):1711-23. [DOI:10.1056/NEJMoa2027071]

9. Chen F, Li J, Li L, Tong L, et al. (2024) Multidimensional biological characteristics of ground glass nodules. Frontiers in Oncology, 2024: 14 - 2024. [DOI:10.3389/fonc.2024.1380527]

10. Mazieres J, Drilon A, Lusque A, Mhanna L, et al. (2019) Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Annals of Oncology, 30(8): 1321-8. [DOI:10.1093/annonc/mdz167]

11. Paik PK, Felip E, Veillon R, Sakai H, et al. (2020) Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations. New England Journal of Medicine, 383(10): 931-43. [DOI:10.1056/NEJMoa2004407]

12. Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, et al. (2018) STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discovery, 8(7): 822-35. [DOI:10.1158/2159-8290.CD-18-0099]

13. Oh MS, Abascal J, Rennels AK, Salehi-Rad R, et al. (2025) Tumor heterogeneity and the immune response in non-small cell lung cancer: Emerging insights and implications for immunotherapy. Cancers, 17(6): 1027. [DOI:10.3390/cancers17061027]

14. Wei Z, Wang Z, Nie Y, Zhang K, et al. (2021) Molecular alterations in lung adenocarcinoma with ground-glass nodules: a systematic review and meta-analysis. Frontiers in Oncology, 2021: 11 - 2021. [DOI:10.3389/fonc.2021.724692]

15. Zhou C, Wu YL, Chen G, Feng J, et al. (2011)Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology, 12(8): 735-42. [DOI:10.1016/S1470-2045(11)70184-X]

16. Ren J, Wang Y, Liu C, Yang L, et al. (2023) Correlation analysis of clinical, pathological, imaging and genetic features of ground-glass nodule featured lung adenocarcinomas between high-risk and non-high-risk individuals. European Journal of Medical Research, 28(1): 478. [DOI:10.1186/s40001-023-01462-3]

17. Al-Arafat T, Mao A, Katsube T, Wang B (2024) Exploring the Role of p53 in Radiosensitivity: A Key Player in Cancer Therapy. Radiation, 4(4): 309-24. [DOI:10.3390/radiation4040023]

18. Jia Z, Wang Y, Xue J, Yang X, et al. (2021) DNA methylation patterns at and beyond the histological margin of early-stage invasive lung adenocarcinoma radiologically manifested as pure ground-glass opacity. Clinical Epigenetics, 13(1): 153. [DOI:10.1186/s13148-021-01140-3]

19. Gillis K, Orellana WA, Wilson E, Parnell TJ, et al. (2025) FoxA1/2-dependent epigenomic reprogramming drives lineage switching in lung adenocarcinoma. Developmental Cell, 60(3): 472-89. [DOI:10.1016/j.devcel.2024.10.009]

20. Kikutake C and Yahara K (2016) Identification of epigenetic biomarkers of lung adenocarcinoma through multi-omics data analysis. PLOS ONE, 11(4): e0152918. [DOI:10.1371/journal.pone.0152918]

21. Bitaraf A, Zafarani A, Jahandideh P, Hakak-Zargar B, et al. (2025) MALAT1 as a molecular driver of tumor progression, immune evasion, and resistance to therapy. Molecular Cancer, 24(1): 245. [DOI:10.1186/s12943-025-02415-6]

22. Arechaga-Ocampo E (2024) Chapter Five - Epigenetics as a determinant of radiation response in cancer. In: Spada S, Galluzzi L, editors. International Review of Cell and Molecular Biology. Academic Press, 2024. p. 145-90. [DOI:10.1016/bs.ircmb.2023.07.008]

23. He Y, Yu F, Tian Y, Hu Q, et al (2022) Single-cell RNA sequencing unravels distinct tumor microenvironment of different components of lung adenocarcinoma featured as mixed ground-glass opacity. Frontiers in Immunology, 2022: 13 - 2022. [DOI:10.3389/fimmu.2022.903513]

24. An H, Fang W, Chen H, Huang W, et al. (2025) Spatial transcriptomics unveils regional heterogeneity and subclonal dynamics in the lung adenocarcinoma microenvironment. Computer Methods and Programs in Biomedicine, 270: 108929. [DOI:10.1016/j.cmpb.2025.108929]

25. Gandara DR, Paul SM, Kowanetz M, Schleifman E, et al. ( 2018) Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nature Medicine, 24(9): 1441-8. [DOI:10.1038/s41591-018-0134-3]

26. Johnson DB, Frampton GM, Ripley RT, Yaeger R, et al. (2016) Targeted next-generation sequencing identifies markers of response to PD-1 blockade. Cancer Immunology Research, 4(11): 959-67. [DOI:10.1158/2326-6066.CIR-16-0143]

27. Tian H, Wang Y, Yang Z, Chen P, et al. (2023) Genetic trajectory and clonal evolution of multiple primary lung cancer with lymph node metastasis. Cancer Gene Therapy, 30(3): 507-20. [DOI:10.1038/s41417-022-00572-0]

28. Wang T, Wang Y, Lu J, Chen J, et al. (2024) Design, synthesis and bioevaluation of dual EGFR-PI3Kα inhibitors for potential treatment of NSCLC. Bioorganic Chemistry, 151: 107714. [DOI:10.1016/j.bioorg.2024.107714]

29. Schuurbiers OCJ, Kaanders JHAM, van der Heijden HFM, Dekhuijzen RPN, et al. (2009) The PI3-K/AKT-Pathway and Radiation Resistance Mechanisms in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 4(6): 761-7. [DOI:10.1097/JTO.0b013e3181a1084f]

30. Zhang Z, Westover D, Tang Z, Liu Y, et al. (2024) Wnt/β-catenin signaling in the development and therapeutic resistance of non-small cell lung cancer. Journal of Translational Medicine, 22(1): 565. [DOI:10.1186/s12967-023-04792-2]

31. Hodson K, Arredondo HM, Humphrey WE, Flanagan DJ, et al. (2025) Targeting Cancer with Paris' Arrow: An Updated Perspective on Targeting Wnt Receptor Frizzled 7. Sci, 7(2): 61. [DOI:10.3390/sci7020061]

32. Del Re M, Tiseo M, D'Incecco A, Camerini A, et al. (2015) KRAS has a role in acquired resistance to EGFR-TKIs in NSCLC: an analysis on circulating tumor DNA. Annals of Oncology, 26: vi84. [DOI:10.1093/annonc/mdv343.34]

33. Li F, Peng X, Zheng L, Liu Y, et al. (2023) YAP nuclear translocation facilitates radiation resistance in nasopharyngeal carcinoma cells. Biochemical and Biophysical Research Communications, 670: 109-16. [DOI:10.1016/j.bbrc.2023.05.101]

34. Brzozowa-Zasada M (2021) The role of Notch ligand, Delta-like ligand 4 (DLL4), in cancer angiogenesis-implications for therapy. European Surgery, 53(6): 274-80. [DOI:10.1007/s10353-021-00707-x]

35. Peng D, Fu M, Wang M, Wei Y, Wei X (2022) Targeting TGF-β signal transduction for fibrosis and cancer therapy. Molecular Cancer, 21(1):104. [DOI:10.1186/s12943-022-01569-x]

36. Morgan D, Garg M, Tergaonkar V, Tan SY, Sethi G (2020) Pharmacological significance of the non-canonical NF-κB pathway in tumorigenesis. Biochimica et Biophysica Acta (BBA). Reviews on Cancer, 1874(2): 188449. [DOI:10.1016/j.bbcan.2020.188449]

37. Ren Y-F, Ma Q, Zeng X, Huang C-X, et al. (2024) Single-cell RNA sequencing reveals immune microenvironment niche transitions during the invasive and metastatic processes of ground-glass nodules and part-solid nodules in lung adenocarcinoma. Molecular Cancer, 23(1): 263. [DOI:10.1186/s12943-024-02177-7]

38. Qu R, Ye F, Hu S, Wang B, et al. (2023) Distinct cellular immune profiles in lung adenocarcinoma manifesting as pure ground glass opacity versus solid nodules. Journal of Cancer Research and Clinical Oncology, 149(7): 3775-88. [DOI:10.1007/s00432-022-04289-3]

39. Kong S, Zhang J, Wang L, Li W, et al. (2025) Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy. Cancer Letters, 611: 217432. [DOI:10.1016/j.canlet.2024.217432]

40. Pai SG, Carneiro BA, Mota JM, Costa R, et al. (2017) Wnt/beta-catenin pathway: modulating anticancer immune response. Journal of Hematology & Oncology, 10(1): 101. [DOI:10.1186/s13045-017-0471-6]

41. Adinolfi S, Patinen T, Jawahar Deen A, Pitkänen S, et al. (2023) The KEAP1-NRF2 pathway: Targets for therapy and role in cancer. Redox Biology, 63: 102726. [DOI:10.1016/j.redox.2023.102726]

42. Melia E and Parsons Jason L (2023) DNA damage and repair dependencies of ionising radiation modalities. Bioscience Reports, 43(10). [DOI:10.1042/BSR20222586]

43. Ragupathi A, Singh M, Perez AM, Zhang D (2023) Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights. Frontiers in Cell and Developmental Biology, 11: 2023. [DOI:10.3389/fcell.2023.1133472]

44. Zhang Y, Chen J, Wang X, Wang H, et al. (2025) Efficacy and safety of Sacituzumab govitecan in solid tumors: a systematic review and meta-analysis. Frontiers in Oncology, 15: 2025. [DOI:10.3389/fonc.2025.1624386]

45. Entezari M, Taheriazam A, Paskeh MDA, Sabouni E, et al. (2023)The pharmacological and biological importance of EZH2 signaling in lung cancer. Biomedicine & Pharmacotherapy, 160: 114313. [DOI:10.1016/j.biopha.2023.114313]

46. Xing W, Sun H, Yan C, Zhao C, et al. (2021) A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules. BMC Cancer, 21(1): 263. [DOI:10.1186/s12885-021-08002-4]

47. Cao H, Ma Z, Li Y, Zhang Y, Chen H (2023) Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features. J Thorac Cardiovasc Surg, 166(6): e479-e99. [DOI:10.1016/j.jtcvs.2023.04.037]

48. Xue R, Li X, Yang L, Yang M, et al. (2024) Evaluation and integration of cell-free DNA signatures for detection of lung cancer. Cancer Letters, 604: 217216. [DOI:10.1016/j.canlet.2024.217216]

49. Yao Y, Yang H, Zhu B, Wang S, et al. (2023) Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer. Respiratory Research, 24(1): 28. [DOI:10.1186/s12931-023-02329-1]

50. Yang W, You N, Jia M, Yeung S-CJ, et al. (2020) Undetectable circulating tumor DNA levels correlate with low risk of recurrence/metastasis in postoperative pathologic stage I lung adenocarcinoma patients. Lung Cancer, 146: 327-34. [DOI:10.1016/j.lungcan.2020.06.009]

51. Warkentin MT, Al-Sawaihey H, Lam S, Liu G, et al. (2024) Radiomics analysis to predict pulmonary nodule malignancy using machine learning approaches. Thorax, 79(4): 307. [DOI:10.1136/thorax-2023-220226]

52. Kim EY, Cha YJ, Lee SH, Jeong S, et al. (2022) Early lung carcinogenesis and tumor microenvironment observed by single-cell transcriptome analysis. Translational Oncology, 15(1): 101277. [DOI:10.1016/j.tranon.2021.101277]

53. Kang DH, Kim Y, Lee JH, Kang HS, Chung C (2025) Spatial Transcriptomics in Lung Cancer and Pulmonary Diseases: A comprehensive review. Cancers, 17(12):1912. [DOI:10.3390/cancers17121912]

54. Hsieh W-C, Budiarto BR, Wang Y-F, Lin C-Y, et al. (2022) Spatial multi-omics analyses of the tumor immune microenvironment. Journal of Biomedical Science, 29(1): 96. [DOI:10.1186/s12929-022-00879-y]

55. Du Y, Ding X, Ye Y (2024) The spatial multi-omics revolution in cancer therapy: Precision redefined. Cell Reports Medicine, 5(9):101740. [DOI:10.1016/j.xcrm.2024.101740]

56. Dong OM, Poonnen PJ, Winski D, Reed SD, et al. (2022 ) Cost-effectiveness of tumor genomic profiling to guide first-line targeted therapy selection in patients with metastatic lung adenocarcinoma. Value in Health, 25(4): 582-94. [DOI:10.1016/j.jval.2021.09.017]

57. Bourke M, McInerney-Leo A, Steinberg J, Boughtwood T, et al. (2025) The cost effectiveness of genomic medicine in cancer control: A Systematic Literature Review. Applied Health Economics and Health Policy, 23(3): 359-93. [DOI:10.1007/s40258-025-00949-w]

58. Xin L, Yue Y, Zihan R, Youbin C, et al. (2023) Clinical application of liquid biopsy based on circulating tumor DNA in non-small cell lung cancer. Frontiers in Physiology, 14: 2023. [DOI:10.3389/fphys.2023.1200124]

59. Trombetta D, Delcuratolo MD, Fabrizio FP, Delli Muti F, et al. (2025) Methylation analyses in liquid biopsy of lung cancer patients: A novel and intriguing approach against resistance to target therapies and immunotherapies. Cancers, 17(18): 3021. [DOI:10.3390/cancers17183021]